TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Laurus Labs Ltd.
LAURUSLABSMid CapNSEBSE
Healthcare · Healthcare
₹1,934.90up 5.50up 0.29 percentas of 28 Aug 2026
Book value ₹98.47Div yield 0.10%
Key metrics
- Market Cap
- 1,04,566.63 ₹ cr
- P/E
- 117.32 x
- P/B
- 19.65 x
- ROE
- 13.49%
- ROCE
- 16.66%
- Debt to Equity
- 0.38 x
- Net Margin
- 11.91%
- Dividend Yield
- 0.10%
- Revenue Growth (YoY)
- 29.10%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE below 20% in each of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue declined year-on-year in 1 of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 27.5% (pledge data not available).
- Debt-to-equity 0.38 — above the Healthcare median of 0.31.
LAURUSLABS
₹1,934.90up 0.29 percent
EOD Synced: 28 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatStable Return Franchise
18.99%ROCE
ROE: 16.77%·P/B: 19.65x
2. Forensic Health & SolvencyPiotroski 9/9 · Strong Health
9/9Piotroski Score
Altman: 4.0 (Safe Zone)
3. Valuation & DCF Spread-94.1% Valuation Premium
₹115DCF Fair Value
CMP: ₹1,934.9
4. Ownership & GovernanceClean Promoter Holding
27.47%Promoter Stake
Pledged: 0.0%·Inst: 38.15%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #34 of 46 in HealthcareQVGM 45/100
Quality (Q)57
ROE, ROCE, Margins & Cash Conversion
Value (V)7
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)26
3Y Sales & EPS Compounded Growth
Momentum (M)98
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #34 of 46 in Healthcare
Valuation
Weak7/100
P/E Ratio:117.32x
P/B Ratio:19.65x
Dividend Yield:0.10%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Weak26/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Moderate57/100
ROE:16.8%
ROCE:19.0%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Strong100/100
Piotroski F-Score:9/9
Altman Z-Score:4.03
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Strong98/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹832.30
From 52W High+0.00%
52-Week High₹1,934.90
Valuation MultiplesCash Flow & Yield
PEG Ratio28.42
Earnings Yield9.41%
Price / FCF—
FCF Yield-0.06%
Payout Ratio1.10%
Net-Net Ratio-4.56
Solvency & SafetyPiotroski & Altman
Piotroski F-Score9/9
Altman Z-Score4.03
Graham Number₹635.14
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▲ +2.18%
DII Stake:▼ 1.07%
OPM Margin:▲ +7.91%
Net Margin:▲ +6.59%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +11.85% | ▲ +29.10% | 22.67% | 4.09% | 7.19% |
| Net Profit Growth | ▲ +31.69% | ▲ +125.49% | 148.04% | 4.00% | -2.01% |
| EPS Growth | ▲ +31.53% | ▲ +125.17% | 181.77% | 4.13% | -1.99% |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — LAURUSLABS
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹118.4
Verdict:Overvalued (-93.9%)
Benjamin Graham Number
₹191.1
-90.1% vs CMPPeter Lynch Fair Value
₹82.7
-95.7% vs CMPReverse DCF Implied Growth
60.0% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹1,934.9
₹0 (Distress)CMP: ₹1,935DCF: ₹118Graham: ₹191
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR6.0%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 6% | ₹587 | 0.8969 | ₹526 |
| Year 2 | 6% | ₹622 | 0.8044 | ₹500 |
| Year 3 | 6% | ₹659 | 0.7214 | ₹476 |
| Year 4 | 6% | ₹699 | 0.6470 | ₹452 |
| Year 5 | 6% | ₹741 | 0.5803 | ₹430 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹127 -93% | ₹149 -92% | ₹163 -92% | ₹180 -91% | ₹227 -88% |
| 11.0% | ₹105 -95% | ₹121 -94% | ₹131 -93% | ₹143 -93% | ₹173 -91% |
| 11.5% | ₹96 -95% | ₹110 -94% | ₹118 -94% | ₹128 -93% | ₹153 -92% |
| 12.0% | ₹88 -95% | ₹100 -95% | ₹107 -94% | ₹116 -94% | ₹137 -93% |
| 13.0% | ₹75 -96% | ₹84 -96% | ₹89 -95% | ₹96 -95% | ₹111 -94% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E117.32current
ReportedComputed, approximate
P/B19.65current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 117.32 | 19.65 |
Analyst Consensus, Price Targets & Forecasts
Analyst Consensus & Recommendations
Aggregated institutional equity research ratings · 31 Aug 2026
Hold(2.85 / 5)
Strong Buy:2
Buy:3
Hold:4
Sell:3
Strong Sell:1
Coverage: 13 contributing analystsScale: 1 (Strong Buy) – 5 (Strong Sell)
Ratings shown are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Balanced risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:30.05%
Analyst Price Targets
12-month forward price consensus · 31 Aug 2026
Upside: -22.89%
Mean Target₹1,492.00vs CMP ₹1,934.90
High Target₹1,980.00+2.3% max upside
Low Target₹810.00-58.1% downside
Median Target₹1,700.0013 estimates
Low: ₹810.00Mean: ₹1,492.00High: ₹1,980.00
Mean Target Current Price (₹1,934.90)
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2024EConsensus
Mean Estimate
—
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹0.68
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹0.43
Low:—
High:—
FY2024EConsensus
Mean Estimate
₹1.40
Low:—
High:—
FY2025EConsensus
Mean Estimate
₹0.23
Low:—
High:—
FY2025E2 Analysts
Mean Estimate
₹0.37
Low:—
High:—
FY2025E2 Analysts
Mean Estimate
₹1.71
Low:—
High:—
FY2025E2 Analysts
Mean Estimate
₹4.33
Low:—
High:—
FY2026E2 Analysts
Mean Estimate
₹3.02
Low:—
High:—
FY2026E2 Analysts
Mean Estimate
₹3.61
Low:—
High:—
FY2026E2 Analysts
Mean Estimate
₹4.67
Low:—
High:—
FY2026E3 Analysts
Mean Estimate
₹5.17
Low:—
High:—
FY2027E1 Analysts
Mean Estimate
₹6.80
Low:—
High:—
FY2027E1 Analysts
Mean Estimate
₹5.58
Low:₹5.00
High:₹5.00
FY2027E1 Analysts
Mean Estimate
₹5.86
Low:₹5.00
High:₹5.00
FY2027E1 Analysts
Mean Estimate
₹7.27
Low:₹7.00
High:₹7.00
FY2028E1 Analysts
Mean Estimate
₹7.28
Low:₹7.00
High:₹7.00
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2024 Forecast | — | — | — | — |
| FY2024 Forecast | ₹0.68 | — | — | — |
| FY2024 Forecast | ₹0.43 | — | — | — |
| FY2024 Forecast | ₹1.40 | — | — | — |
| FY2025 Forecast | ₹0.23 | — | — | — |
| FY2025 Forecast | ₹0.37 | — | — | 2 |
| FY2025 Forecast | ₹1.71 | — | — | 2 |
| FY2025 Forecast | ₹4.33 | — | — | 2 |
| FY2026 Forecast | ₹3.02 | — | — | 2 |
| FY2026 Forecast | ₹3.61 | — | — | 2 |
| FY2026 Forecast | ₹4.67 | — | — | 2 |
| FY2026 Forecast | ₹5.17 | — | — | 3 |
| FY2027 Forecast | ₹6.80 | — | — | 1 |
| FY2027 Forecast | ₹5.58 | ₹5.00 | ₹5.00 | 1 |
| FY2027 Forecast | ₹5.86 | ₹5.00 | ₹5.00 | 1 |
| FY2027 Forecast | ₹7.27 | ₹7.00 | ₹7.00 | 1 |
| FY2028 Forecast | ₹7.28 | ₹7.00 | ₹7.00 | 1 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Clean Governance & Solvency
Financial Strengths & Catalysts
3 Factors- •Company maintains conservative leverage with D/E of 0.48x.
- •Strong cash generation: Operating Cash Flow is 182.7% of reported Net Profit.
- •High institutional backing: FIIs & DIIs hold a combined 38.1%.
Risk Factors & Watchouts
1 Watchout- •Stock is trading at an elevated valuation multiple of 117.3x P/E.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score9 / 9
● Strong (High Quality)
Altman Z-Score4.03
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-3.13
● Low Risk (Clean Accounting)
Cash flows closely match reported earnings with conservative accruals.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
62.3%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
8.1%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
65.9%of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹889 CrInflow
889
+ D&A Non-Cash Charge₹480 CrAdd-back
480
Working Capital Adjustment₹255 Cr+ Cash
255
= Operating Cash Flow (CFO)₹1,624 CrOperating Cash
1,624
- Capital Expenditures (CapEx)-₹1,070 CrReinvestment
1,070
= Free Cash Flow (FCF)₹554 CrFree Cash Flow
554
- Dividends & Debt Repayment-₹196 CrCapital Return
196
= Net Change in Cash₹358 CrNet Balance
358
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2018-201931 Mar 2019 | 2019-202031 Mar 2020 | 2020-202131 Mar 2021 | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,406.45 | ₹2,831.72 | ₹4,813.51 | ₹4,935.57 | ₹6,040.55 | ₹5,040.83 | ₹5,553.96 | ₹6,812.90 |
| Operating profit | ₹681.29 | ₹382.92 | ₹1,346.46 | ₹1,173.92 | ₹1,293.64 | ₹394.85 | ₹625.19 | ₹1,305.62 |
| OPM | 20.00% | 13.52% | 27.97% | 23.78% | 21.42% | 7.83% | 11.26% | 19.16% |
| Net profit | ₹444.40 | ₹255.27 | ₹983.58 | ₹827.52 | ₹790.11 | ₹160.55 | ₹358.32 | ₹888.79 |
| EPS | 8.10 | 4.80 | 18.29 | 15.37 | 14.65 | 3.00 | 5.87 | 16.54 |
| Net margin | 13.05% | 9.01% | 20.43% | 16.77% | 13.08% | 3.19% | 6.45% | 13.05% |
| ROE | 21.56% | 14.42% | 37.87% | 24.69% | 19.57% | 3.91% | 8.01% | 16.77% |
| ROCE | 24.91% | 18.61% | 40.88% | 27.38% | 24.74% | 7.49% | 10.79% | 18.99% |
| Debt / equity | 0.33 | 0.61 | 0.57 | 0.53 | 0.50 | 0.63 | 0.62 | 0.48 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y | 5Y |
|---|---|---|---|
| Revenue | 22.67% | 4.09% | 7.19% |
| Net profit | 148.04% | 4.00% | -2.01% |
| EPS | 181.77% | 4.13% | -1.99% |
Each column only appears when 8 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Total assets | ₹3,747.10 | ₹3,750.32 | ₹5,750.69 | ₹6,968.04 | ₹7,660.40 | ₹8,387.03 | ₹9,335.57 | ₹10,511.19 |
| Total liabilities | ₹1,686.19 | ₹1,980.54 | ₹3,153.14 | ₹3,616.85 | ₹3,622.87 | ₹4,276.08 | ₹4,863.01 | ₹5,211.13 |
| Total equity | ₹2,060.90 | ₹1,769.78 | ₹2,597.55 | ₹3,351.19 | ₹4,037.53 | ₹4,110.95 | ₹4,472.56 | ₹5,300.06 |
| Total debt | ₹674.48 | ₹1,079.43 | ₹1,481.69 | ₹1,776.66 | ₹2,015.09 | ₹2,577.40 | ₹2,763.73 | ₹2,518.48 |
| Cash | ₹449.65 | ₹1.69 | ₹48.46 | ₹53.93 | ₹19.34 | ₹121.81 | ₹91.11 | ₹112.66 |
| Current assets | ₹1,686.19 | ₹1,812.05 | ₹3,074.86 | ₹3,344.61 | ₹3,461.68 | ₹3,834.97 | ₹4,332.32 | ₹4,829.21 |
| Current liabilities | ₹936.77 | ₹1,692.37 | ₹2,457.15 | ₹2,681.01 | ₹2,432.26 | ₹3,112.28 | ₹3,539.72 | ₹3,635.43 |
| Inventory | ₹340.65 | ₹905.22 | ₹1,575.45 | ₹1,760.30 | ₹1,684.81 | ₹1,845.41 | ₹1,936.54 | ₹2,342.16 |
| Receivables | ₹408.77 | ₹791.42 | ₹1,306.06 | ₹1,354.18 | ₹1,580.44 | ₹1,662.92 | ₹2,007.16 | ₹2,155.04 |
| Payables | ₹306.58 | ₹615.61 | ₹1,178.69 | ₹876.37 | ₹710.65 | ₹1,051.24 | ₹977.08 | ₹1,278.44 |
| Net PP&E | ₹1,498.84 | ₹1,774.02 | ₹2,277.17 | ₹3,208.56 | ₹3,700.17 | ₹4,047.53 | ₹4,315.96 | ₹4,879.22 |
| Retained earnings | ₹1,545.68 | ₹984.62 | ₹1,806.80 | ₹2,552.71 | ₹3,232.68 | ₹3,304.89 | ₹3,654.33 | ₹4,455.72 |
Cash flow
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | ₹555.49 | ₹347.41 | ₹733.00 | ₹911.10 | ₹993.90 | ₹665.69 | ₹601.65 | ₹1,623.50 |
| Capital expenditure | ₹204.39 | ₹-222.19 | ₹-688.77 | ₹-876.84 | ₹-990.16 | ₹-678.31 | ₹-641.00 | ₹-1,069.95 |
| Free cash flow | ₹351.11 | ₹125.22 | ₹44.23 | ₹34.26 | ₹3.74 | ₹-12.62 | ₹-39.35 | ₹553.55 |
| OCF / net profit | 1.25 | 1.36 | 0.75 | 1.10 | 1.26 | 4.15 | 1.68 | 1.83 |
| FCF / Capex intensity | 0.06 | 7.85 | 14.31 | 17.77 | 16.39 | 13.46 | 11.54 | 15.70 |
Income statement detail
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | ₹1,192.26 | ₹1,250.92 | ₹2,458.39 | ₹2,482.78 | ₹2,875.74 | ₹2,203.59 | ₹2,691.15 | ₹3,678.12 |
| Cost of revenue | ₹2,214.19 | ₹1,580.80 | ₹2,355.12 | ₹2,452.79 | ₹3,164.81 | ₹2,837.24 | ₹2,862.81 | ₹3,134.78 |
| EBITDA | ₹749.42 | ₹570.24 | ₹1,551.53 | ₹1,425.41 | ₹1,617.72 | ₹779.43 | ₹1,055.28 | ₹1,785.67 |
| Income before tax | ₹591.05 | ₹293.61 | ₹1,301.11 | ₹1,083.85 | ₹1,108.94 | ₹236.36 | ₹484.29 | ₹1,181.88 |
| Interest expense | ₹170.32 | ₹84.33 | ₹38.88 | ₹74.02 | ₹165.83 | ₹165.73 | ₹191.93 | ₹127.56 |
| Tax expense | ₹146.65 | ₹38.34 | ₹317.29 | ₹251.42 | ₹312.30 | ₹68.15 | ₹129.88 | ₹292.03 |
| D&A | ₹136.26 | ₹187.32 | ₹205.07 | ₹251.49 | ₹324.08 | ₹384.58 | ₹430.09 | ₹480.05 |
| EBITDA margin | 22.00% | 20.14% | 32.23% | 28.88% | 26.78% | 15.46% | 19.00% | 26.21% |
Financial ratios
| Metric | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.80 | 1.07 | 1.25 | 1.25 | 1.42 | 1.23 | 1.22 | 1.33 |
| Quick ratio | 1.44 | 0.54 | 0.61 | 0.59 | 0.73 | 0.64 | 0.68 | 0.68 |
| Interest coverage | 4.00 | 4.54 | 34.63 | 15.86 | 7.80 | 2.38 | 3.26 | 10.24 |
| Inventory days | 45.00 | 209.01 | 244.17 | 261.95 | 194.31 | 237.40 | 246.90 | 272.71 |
| Receivable days | 35.00 | 102.01 | 99.04 | 100.15 | 95.50 | 120.41 | 131.91 | 115.46 |
| Payable days | 40.00 | 142.14 | 182.68 | 130.41 | 81.96 | 135.24 | 124.57 | 148.86 |
| Cash conversion cycle | 40.00 | 168.88 | 160.53 | 231.68 | 207.85 | 222.58 | 254.24 | 239.31 |
| Working capital days | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Fixed asset turnover | 2.27 | 1.60 | 2.11 | 1.54 | 1.63 | 1.25 | 1.29 | 1.40 |
| ROA | 11.86% | 6.81% | 17.10% | 11.88% | 10.31% | 1.91% | 3.84% | 8.46% |
| ROIC | 19.44% | 11.69% | 25.26% | 17.77% | 15.40% | 4.28% | 6.40% | 12.76% |
| Gross margin | 35.00% | 44.18% | 51.07% | 50.30% | 47.61% | 43.71% | 48.45% | 53.99% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
Balanced Return EngineFY2025-2026
Net marginProfitability
13.05%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.65
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.98
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
16.77%
Reported: 16.77%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 08 May 2026 | dividend | 60% |
| 2025 | 31 Oct 2025 | dividend | 40% |
| 09 May 2025 | dividend | 40% | |
| 2024 | 06 Nov 2024 | dividend | 20% |
| 08 May 2024 | dividend | 20% | |
| 2023 | 02 Nov 2023 | dividend | 20% |
| 10 May 2023 | dividend | 60% | |
| 2022 | 04 Nov 2022 | dividend | 40% |
| 11 May 2022 | dividend | 60% | |
| 2021 | 18 Nov 2021 | dividend | 40% |
| 12 May 2021 | dividend | 40% | |
| 09 Feb 2021 | dividend | 20% | |
| 2020 | 11 Nov 2020 | dividend | 40% |
| 30 Sept 2020 | split | 2:10 | |
| 03 Jul 2020 | dividend | 10% | |
| 25 Mar 2020 | dividend | 15% | |
| 2019 | 05 Jul 2019 | dividend | 15% |
| 05 Jul 2019 | dividend | 15% | |
| 2018 | 02 Jul 2018 | dividend | 15% |
| 2017 | 10 Jul 2017 | dividend | 15% |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 12 dividend distributions
Latest Year DPS:₹1.20
Yield on CMP:0.06%
3Y Dividend CAGR:-9.1%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹9.20
₹1.2
2026
₹1.6
2025
₹0.8
2024
₹1.6
2023
₹2.0
2022
₹2.0
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 08 May 2026 | ₹1.20 | Interim |
| 31 Oct 2025 | ₹0.80 | Interim |
| 09 May 2025 | ₹0.80 | Interim |
| 06 Nov 2024 | ₹0.40 | Interim |
| 08 May 2024 | ₹0.40 | Interim |
| 02 Nov 2023 | ₹0.40 | Interim |
| 10 May 2023 | ₹1.20 | Interim |
| 03 Nov 2022 | ₹0.80 | Interim |
| 10 May 2022 | ₹1.20 | Interim |
| 17 Nov 2021 | ₹0.80 | Interim |
| 11 May 2021 | ₹0.80 | Interim |
| 08 Feb 2021 | ₹0.40 | Interim |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
HealthcareCompare Peers in Studio
Market Cap1,04,566.63 ₹ cr
Beats 92% of 65 industry peers · median 21,553.63 ₹ cr
P/E117.32 x
Beats 93% of 60 industry peers · median 48.58 x
P/B19.65 x
Beats 94% of 62 industry peers · median 6.13 x
ROE13.49%
Beats 46% of 65 industry peers · median 14.40%
ROCE16.66%
Beats 51% of 65 industry peers · median 16.38%
Debt to Equity0.38 x
Beats 68% of 65 industry peers · median 0.31 x
Net Margin11.91%
Beats 34% of 65 industry peers · median 13.19%
Dividend Yield0.10%
Beats 9% of 53 industry peers · median 0.44%
Revenue Growth (YoY)29.10%
Beats 80% of 64 industry peers · median 19.05%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.61 L | 41.52 | 5.51 |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.88 L | 79.00 | 20.38 |
Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹1.27 L | 65.49 | 13.41 |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.16 L | 23.78 | 4.42 |
Cipla Ltd.CIPLA | ₹1.14 L | 29.66 | 3.34 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Filings & Document Vault
SEBI LODR VerifiedAudited Annual Reports, Investor Decks, Earnings Concall Transcripts, and Board Resolutions for Laurus Labs Ltd. (LAURUSLABS)
Indexed Documents5 Filings
Latest Disclosure30 Jul 2026
Press Release30 Jul 2026
Laurus Labs Ltd: Press Release: Business Updates and New Strategic Initiatives
AGM / EGM23 Jun 2026
Laurus Labs Ltd: Notice of Annual General Meeting and Record Date for Dividend
Concall Transcript18 Jun 2026
Laurus Labs Ltd: Transcript of Earnings Conference Call with Institutional Investors
Shareholding08 May 2026
Laurus Labs Ltd: Quarterly Statement of Shareholding Pattern filed with NSE/BSE
News
- IndianAPIWelspun Corp, Piramal Finance, Divis Labs among 12 BSE 500 stocks that jumped to their record highs today; do you own?
Some 17 stocks scaled their 52-week highs in the BSE 500 index, among which 12, including Welspun Corp, Piramal Finance, and Divis Laboratories, jumped to their record highs.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 28 August 2026
The Indian stock market is set to open flat, following weak global trends. Major indices Nifty 50 and Sensex ended lower, with Nifty closing below 24,100. Analyst Chandan Taparia suggests cautious trading within defined ranges and recommends buying Sona BLW, Laurus Labs, and BHEL shares.
- IndianAPIStock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Wednesday, 26 August
The Indian stock market is expected to open higher on 26 August, following positive global cues. The Nifty and Sensex ended the previous session positively, aided by falling oil prices amid diplomatic efforts in the Strait of Hormuz.
- IndianAPI15 Nifty 500 stocks that doubled investors’ money since last Independence Day: Do you own any?
Despite a challenging year for Indian equities, marked by a 2% dip in the Nifty 50, the broader Nifty 500 index has revealed surprising winners. Discover the 15 stellar stocks that have doubled investor money, amidst geopolitical and economic tides.
- IndianAPIStock market today: Gift Nifty hints a flat start; seven day trading stocks to buy on Thursday, 30 July
Indian stock market indices Sensex and Nifty 50 are expected to open flat due to weak global cues. The Gift Nifty indicates a subdued start, while the Fed decision to maintain interest rates leaves uncertainty in markets. Gold prices rise amid geopolitical tensions.
- IndianAPITop Gainers & Losers on 27 July: CarTrade Tech, Laurus Labs, Infosys, Atul, TBO Tek, Anant Raj among top gainers
The Indian stock market rebounded on July 27, with benchmark indices rising about 1% as crude oil prices fell due to reduced tensions in the Middle East. Broad-based sector gains were seen, spurred by Nifty Media, IT, and Realty, reversing a recent downturn.
- IndianAPICipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street
Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each.
- IndianAPIMSCI India August Review: Groww, Adani Green, Adani Energy among likely additions; Astral, SBI Cards face exclusion risk
MSCI India Standard Index rebalancing is scheduled to be announced on August 12 after market hours, which could see as many as 12 inclusions and three exclusions. This is estimated to lead to potential passive inflows of around $2.3 billion. The changes will take effect from August 31.
- IndianAPIStock market today: Gift Nifty hints a gap-down start; eight day trading stocks to buy on Tuesday, 14 July
Indian benchmark indices are expected to have a subdued opening due to weak global cues. Investor sentiment is pressured by rising crude oil prices amid geopolitical tensions in the US-Iran conflict, affecting corporate earnings outlook and raising inflation concerns.
- IndianAPIStock market today:Gift Nifty hints muted start;US tech stocks sell-off, Kospi rebounds to oil prices - 8 stocks to buy
Indian stock market indices Sensex and Nifty 50 are expected to open subdued due to mixed global signals and recent technology stock sell-offs. Investor sentiment remains cautious ahead of US-Iran negotiations, impacting the market outlook amid ongoing volatility in equities.
- IndianAPITop Gainers & Losers on June 23: Vedanta, Hindustan Zinc, Infosys, TCS, Bank of Baroda among top losers
The Indian stock market fell sharply on June 23, influenced by global market weakness and a retreat in technology stocks. The Nifty 50 declined 1.16%, marking its biggest drop in nearly four weeks, with all sectoral indices closing lower amid profit-booking and a stronger US dollar.
- IndianAPISun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row
The Nifty Pharma index rose 1.4% on 8 June, defying the broader market selloff, supported by heavyweight stocks like JB Chemicals and Alkem Laboratories. Despite some losses in others, analysts suggest pharma stocks are resilient during market instability due to consistent healthcare demand.
- IndianAPIShares to buy or sell: Chandan Taparia of Motilal Oswal recommends 3 stocks to buy today amid RBI policy - 5 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 5 June 2026 - BSE, Laurus Labs and Exide Industries shares.
- IndianAPIGland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?
The Nifty Pharma index has surged nearly 11% over the past month, significantly outperforming the Nifty 50, which declined 3.6% during the same period. On a year-to-date (YTD) basis, the Nifty Pharma index has gained 9.4%, while the benchmark Nifty 50 has fallen by an equal margin.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.